Off an SEC filing from dec 2009Due to the complexity of RECAF technology, we believe that our proprietary know-how for developing the technology and working with the RECAF family of molecules is critical and extends beyond patented information. Accordingly, we include know-how in our licensing packages in order to obtain royalties in countries where we do not have patent protection.
KEY POINT: DUE TO THE COMPLEXITY OF RECAF Like I said earlier, if it were easy don't you think that someone would have cracked this wide open by now? It will happen.
Opportunity stated: "Maybe he has sufficient data from his animal studies (mice) that he can proceed with an application for the FDA for therapeutics."
How long have you been investing in medical stocks and you still do not understand what is required for FDA approval of a drug?
News 
Market Data 
Discover 
